The Cannabis / Vice Letter JUNE 6, 2017


By: Mark Leibovit |

Maple Leaf Announces Termination of TheraCann

Maple Leaf Green World Inc. (the “Maple Leaf” or the “Company”) announces that it will discontinue all future business relations with TheraCann International Benchmark Corporation (“TheraCann”) due to billing irregularities and overbilling.

Maple Leaf continues to execute its strategy of diligent deployment of capital, this includes reviewing all requests for payment. Unfortunately, TheraCann’s contractual and invoicing practices are inconsistent with their representations. Accordingly, discontinuation of this business relationship is in the best interest of Maple Leaf and its shareholders.

Maple Leaf is reviewing all services alleged to have been provided by TheraCann, and will pursue all necessary legal remedies to ensure the Maple Leaf and related stake holders are protected. Maple Leaf reiterates that the Company continues to work for the best interests of its investors, and in the opinion of management, termination of TheraCann contract is not material to Maple Leaf.

Maple Leaf is a public Canadian company that focuses on the cannabis industry in North America with Company currently operates 3 cannabis projects: B.C. Canada, California and Nevada U.S.A. With over 10 years of extensive greenhouse management experience, it applies its eco-agriculture knowledge and cultivation technology to produce contaminant-free organic cannabis products. Maple Leaf’s long-term objective is to produce cannabis oil and export its products to approved countries.


CanniMed Therapeutics Inc. Announces 2017 Second Quarter Results Release Date

CanniMed Therapeutics Inc. (TSX:CMED) (“CanniMed” or the “Company”) announces that it plans to release its financial results for the three and six months ended April 30, 2017 before markets open on Monday, June 12, 2017.

CanniMed is a Canadian-based, international plant biopharmaceutical company and a leader in the Canadian medical cannabis industry, with 15 years of pharmaceutical cannabis cultivation experience, state-of-the-art, GMP-compliant production process and world class research and development platforms with a wide range of pharmaceutical-grade cannabis products. In addition, the Company has an active plant biotechnology research and product development program focused on the production of plant-based materials for pharmaceutical, agricultural and environmental applications.

The Company, through its subsidiaries, was the first producer to be licensed under the Marihuana for Medical Purposes Regulations, the predecessor to the current Access to Cannabis for Medical Purposes Regulations. It was the sole supplier to Health Canada under the former medical marijuana system for 13 years, and has been producing safe and consistent medical marijuana for thousands of Canadian patients, with no incident of product diversion or recalls.

ABcann Global (TSXV: ABCN) Target Price Set At $2.25 as Coverage is Initiated

Now that shares of ABcann Global Corporation (TSXV: ABCN) are trading on the venture arm of the Toronto Stock Exchange (TSX), the company is creating more buzz than ever. On the same day it launched its initial public offering (IPO) (May 4), industry analysts PI Financial initiated coverage of the stock with a decidedly bullish report ( on the company. PI has put a “Buy” rating on the stock and set a one-year price target of $2.25, implying a return of well over 100 percent. The investment bank backs up this sunny prognosis with an in-depth look at ABcann’s value chain and Canada’s cannabis industry, by some accounts set to grow to $8 billion in sales by 2024.

ABcann Global recently acquired all the outstanding stock of ABcann Medicinals, a Canadian medical marijuana company licensed to carry on business as a producer and marketer of medical cannabis. ABcann Medicinals has strong fundamentals. It was a first mover in the Canadian cannabis space, obtaining a cultivation license in March 2014, just six months after Health Canada began inviting applications. In addition, it has collaborated with the University of Guelph in studies of the cannabis cultivation process. Consequently, the company has developed substantial institutional expertise, particularly in controlling…


AmeriCann Completes Successful 3-Year Partnership with Licensed Colorado Cannabis Producer

AmeriCann, Inc. (OTCQX: ACAN), an Agricultural-Technology company that is developing the next generation of sustainable, state-of-the-art medical cannabis cultivation properties, announced today it has completed a very successful three-year partnership with a licensed Colorado cannabis producer that has resulted in exceptional returns to the company.

In 2014, AmeriCann contributed $1,000,000 in secured funding for the final design and construction of a 15,000 square foot state-of-art cultivation and processing facility in Denver, CO. AmeriCann’s Preferred Partner, 4900 Jackson, LLC, has been a licensed medical cannabis producer in Colorado since 2010.

With the final payment made in May of 2017, AmeriCann received total distributions over the term of the agreement of $1,457,000 from consulting fees, interest and principal repayment. The average annual returns exceeded 15% over the 3 years.

“Our partnership with AmeriCann has been excellent,” stated John Ray, managing partner of 4900 Jackson, LLC. “I learned first-hand of AmeriCann’s commitment to developing the most efficient, technologically advanced cannabis cultivation facilities possible. The innovations in cultivation technology that AmeriCann has developed for its development in Massachusetts are the future of the industry.”

“We are extremely pleased with our partnership with 4900 Jackson, LLC. The financial returns were excellent for our shareholders. As an early-mover in the Colorado market our team gained invaluable first-hand knowledge with innovative cultivation systems and the market dynamics from the most mature regulated market in the nation,” commented Tim Keogh, President and CEO of AmeriCann. “In 2016, Colorado was a $1.2 billion market, which continues to grow, and to participate in such a dynamic market was an excellent experience that we will continue to leverage in new markets throughout the country.”

AmeriCann’s flagship project, the Massachusetts Medical Cannabis Center (“MMCC”), is 47 miles from Boston in the midst of the rapidly growing Massachusetts medical cannabis market. The MMCC project is approved for 1 million square feet, which will be developed in phases and is expected to be one of the most technologically advanced cultivation facilities in the nation. The company is planning to replicate the Cannopy platform in additional states.

About AmeriCann:

AmeriCann (OTCQX: ACAN) is a publicly traded Agricultural Technology (Ag-Tech) company that is developing a new generation of sustainable, state-of-the-art medical cannabis cultivation and processing properties. The Company has over 1,000,000 square feet of facilities in the planning and design stages of development.


Cannabis Wheaton (CBW.V) (KWFLF) terminated its previous engagement letter with Eight Capital and Canaccord Genuity in connection with its previously announced best efforts private placement of special warrants” and convertible debenture units. The decision to terminate the letter was mutual.

Over the last week, Cannabis Wheaton has been the subject of multiple inflammatory false or misleading reports. In these reports, the company as well Canaccord and Eight were referenced and targeted about various matters. Cannabis Wheaton also said it has not been contacted by law enforcement or any other regulatory agency and that any allegations being published are entirely without merit.


Golden Leaf Holdings (GLH.CN) (GLDFF) closed its previously announced $35 million best efforts private placement of subscription receipts and sold 125,892,857 at $0.28 each.

Canaccord Genuity acted as the lead agent for a syndicate of agents including Echelon Wealth Partners and Mackie Research Capital. AC Group Financial acted as an advisor to Golden Leaf (and its four previous acquisitions). All securities issued are subject to a statutory hold period of four months and one day, expiring on October 3rd.

For the services provided by the agents in the offering, the agents received a cash commission of $2,467,500, (50% was paid on closing and the other 50% will be payable upon satisfaction of the escrow release conditions) and 8,812,500 compensation warrants. Pursuant to the terms of the agency agreement, Golden Leaf is also proposing to issue and sell, on a brokered, private placement basis, up to C$5,000,000 of units (comprised of one common share and one-half of one warrant). The net proceeds will also be used to fund other recently announced acquisitions and for existing operations.


Aurora Cannabis (ACB.V) (ACBFF) and Radient Technologies (RTI.V) announced the successful completion of its joint venture research activity that confirms the effectiveness of Radient’s proprietary technology and associated continuous flow design for extracting cannabinoids

The study was conducted in two phases: bench-scale screening experiments of MAP extraction conditions; and scaled-up experiments under preferred extraction conditions. The analytical data from the research project were verified and confirmed by Anandia Labs. Findings include: Consistently high extraction efficiencies of up to 98% observed Very short processing times of as little as five minutes were achieved, (compared to approximately 6 hours for existing commercial technologies) Consistently high purity levels for the extracts produced, at least on par with those achieved using conventional methods The research data indicate that throughputs more than 1,500 kg per day can potentially be achieved, many times higher than conventional methods. Replication of this tech in other jurisdictions on a larger or smaller scale is feasible
Extract profiles show near full preservation of cannabinoid and terpene profiles Based on these results, Radient and Aurora have agreed to negotiate an exclusive development and commercialization agreement for the use of Radient’s technology, and to continue their exclusive partnership for additional scientific studies of cannabis and hemp products. Radient also will make the first quarterly interest payment of $50,000 to Aurora through the issuance of additional units to Aurora


Insys Therapeutics (INSY) responded to recent media reports highlighting concerns with its past commercial practices and former employees. The company plans to help address the opioid epidemic by developing innovative products. These solutions include cannabidiol for the treatment of opioid dependence, cannabidiol for the treatment of pain, and naloxone nasal spray for the treatment of opioid overdose.

Insys has committed significant resources to these efforts including seeking guidance and input from nearly 30 researchers across the country and has ongoing collaborations with leading academic institutions.

Insys President and CEO Saeed Motahari said, “We remain committed to cultivating a culture of trust, transparency and ethical behavior while executing against our mission of improving the quality of care for patients in need. As the new CEO, I believe it is imperative that we learn from the past. The Company has taken appropriate steps to strive to ensure that ethical standards of conduct and patient interests are at the heart of all business decisions. The Company continues to demonstrate its commitment to patients by investing over 30% of 2016 revenue in R&D programs and is on track to invest over 40% in R&D in 2017.”


mCig (MCIG) issued a fiscal year 2017 recap, highlights, successes and fiscal year 2018 outlook. Highlights include:

Generated $1.5 million in net income on $4.5 million in revenue, Cash and cash equivalents of $1.6 million and $6.8 million in assets, mCig has established 4 targets to measure its performance this year. Its strategy aims to: Take steps to increase revenues and profits; Reach 1 million active combined customers across all segments; Spin-off one subsidiary into a publicly traded company, offering a share dividend; And strategically enable company to conduct business in diversified sectors, both inside and out of the cannabis industry.

Grow Contractors was its fastest and largest growing segment in 2017 and generated more than $1.1 million in working capital. Grow Contractors has successfully completed its first two contracts, Sin City and Green Leaf Farms. It continues to consult for both groups and is working on hiring and building added partnership opportunities in addition to construction. Solaris and Forest Grove projects are full steam ahead and expected to finish Phase I by September. Grow Contractors also completed various smaller projects in Washington and Oregon in FY2017.

MCIG continues to develop and strengthen its cannabis supply venture, Cannabiz Supply. The business has grown in various areas — selling state mandated and custom packaging, office, dispensary supplies, and vape products. The company has gained multiple accounts with distribution to every dispensary, major grower, and production facility in Nevada.
In April, MCIG launched, a mobile application available on both Android and Apple devices. MCIG anticipates revenue in FY2018 from advertising, microtransactions, payment processing, and retail sales through the new platform.

Since its acquisition of VitaCig in June 2016, MCIG revenue has grown to $1 million annually. They expect this to double this year.


PUF Ventures Inc. (CSE: PUF) (PUFXF) sold its wholly owned mineral asset to a publicly traded resource company, as previously announced in January. The sale of this non-core asset will streamline PUF’s operational focus and positions it as a pure-play bio medical cannabis company.

PUF recently entered an agreement with Canopy Growth’s Canopy Rivers and is an advanced Stage 5 ACMPR license applicant. PUF plans to focus entirely to the advancement of our cannabis business and related VapeTronix technologies


Lexaria Bioscience (LXRP) appointed Allan Spissinger as its new CFO, Secretary, and Treasurer. He was granted 200,000 stock options (exercise price of $0.37).

Lexaria also announced that it has received $1,540 for the exercise of 11,000 warrants at $0.14 and settled $12,000 of debt through the issuance of 35,294 shares at $0.34. The company will use the proceeds for general corporate purposes.

Cannabis Stocks Finance